Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia

Appendix A: Decision paper considered by the Institute's Guidance Executive (PDF 77 KB)

Review Decision - May 2010 information

Appendix A: Decision paper considered by the Institute's Guidance Executive (PDF 77 KB)

Review Proposal - January 2010 information

Appendix A: provisional matrix of consultees and commentators (PDF 32 KB)

Appendix B: proposal paper presented to NICE's Guidance Executive (PDF 203 KB)

Leukaemia (lymphocytic) - fludarabine: Final appraisal determination information

Leukaemia (lymphocytic) - fludarabine: Final appraisal determination document (PDF 78 KB)

Leukaemia (lymphocytic) - fludarabine: Final appraisal determination - Response to consultee and commentator comments and public and web comments (PDF 181 KB)

Leukaemia: Final appraisal determination - consultee and commentator comments

Leukaemia: FAD - consultee and commentator comments: Department of Health (PDF 23 KB)

Leukaemia: FAD - consultee and commentator comments: Royal College of Pathologists (PDF 43 KB)

Leukaemia: FAD - consultee and commentator comments: Children with leukaemia (PDF 239 KB)

Leukaemia: FAD - consultee and commentator comments: Cancer backup (PDF 30 KB)

Leukaemia: FAD - consultee and commentator comments: British committee for standards in haematology (PDF 20 KB)

Leukaemia: FAD - consultee and commentator comments: Schering Health Care Ltd - MHRA update (PDF 17 KB)

Leukaemia: FAD - consultee and commentator comments: Schering Health Care Ltd (PDF 38 KB)

Leukaemia: Final appraisal determination - expert comments

Leukaemia: FAD - expert comments: Dr Howard Pearce on the evaluation report (PDF 13 KB)

Leukaemia: FAD - expert comments: Dr Howard Pearce on the ACD (PDF 13 KB)

Leukaemia: FAD - expert comments: Dr Andrew Pettit (PDF 13 KB)

Leukaemia: FAD - expert comments: Professor Terry Hamblin (PDF 25 KB)

Leukaemia: FAD - expert comments: Jane Barnard (PDF 14 KB)

Leukaemia (lymphocytic) - fludarabine (appraisal consultation document) information

Evidence considered

Leukaemia (lymphocytic) - fludarabine: pre meeting briefing (PDF 74 KB)

Leukaemia (lymphocytic) - fludarabine: pre meeting briefing erratum (PDF 18 KB)

Leukaemia (lymphocytic) - fludarabine: evidence review group report (PDF 673 KB)

Expert written personal statements

Pettitt (PDF 43 KB)

Pearce (PDF 45 KB)

Hamblin (PDF 47 KB)

Barnard (PDF 77 KB)

NICE clarification and responses

Schering Health Care Ltd - response 2 (PDF 159 KB)

Schering Health Care Ltd - response (PDF 78 KB)

NICE Clarification letter (PDF 41 KB)

Manufacturer submission

Schering Health Care Ltd - Appendices (PDF 534 KB)

Schering Health Care Ltd - Submission (PDF 1.27 MB)